4D Molecular Therapeutics, Inc. Income Statement
FDMT|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
4D Molecular Therapeutics, Inc. reported $37,000 in revenue and $161M in net loss for FY2025. Revenue has declined at a 64.9% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $37.0K | $20.7M | $3.1M | $18.0M | $13.6M | $7.0M |
| SG&A Expense | $46.6M | $36.5M | $32.9M | $28.0M | $17.2M | $13.9M |
| R&D Expense | $141.3M | $97.1M | $80.3M | $61.4M | $53.0M | $38.7M |
| Operating Income | -$187.8M | -$112.9M | -$110.0M | -$71.3M | -$56.7M | -$50.8M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$160.9M | -$100.8M | -$107.5M | -$71.3M | -$56.7M | -$49.3M |
| EPS (Basic) | -$2.98 | -$2.58 | -$3.32 | -$2.57 | - | - |
| EPS (Diluted) | -$2.98 | -$2.58 | -$3.32 | -$2.57 | -$8.82 | -$9.59 |
| Shares Outstanding | 45.8M | 43.1M | 32.6M | 32.2M | 26.7M | 5.2M |
| Operating Margin | -507678.4% | -544.7% | -3516.5% | -395.5% | -416.3% | -726.6% |
| Profit Margin | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% | -705.8% |